Merck Reports real-world evidence Data for Liraglutide in Cystic fibrosis

Merck today announced real-world evidence results for Liraglutide in patients with Cystic fibrosis. The study demonstrated that Liraglutide improves quality of life measures compared to standard of care or placebo. These results provide important insights into the treatment of Cystic fibrosis and support the continued development of Liraglutide in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Liraglutide was consistent with previous observations, with no new safety signals identified.